To access this element change to forms mode OFF
Grant Award View - GA89316
Bone Loss Prevention with Zoledronic Acid or Denosumab in Critically Ill...
GA ID:
GA89316
Agency:
Department of Health and Aged Care
Approval Date:
25-May-2020
Publish Date:
29-Jun-2020
Category:
Health and Medical Research
Grant Term:
1-Jun-2020 to 31-May-2025
Value (AUD):
$1,905,282.70
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 19/20 1.1 Health Policy Research and Analysis
Grant Program:
2019_MRFF_RCRDUN_RCRDUN_2020
Grant Activity:
Bone Loss Prevention with Zoledronic Acid or Denosumab in Critically Ill Women – A Randomised Controlled Trial (Bone Zone)
Purpose:
Women over 50-years of age are at high risk of osteoporosis and fragility fractures after life-threatening critical illness. There are effective medications to prevent this, however few women receive them during critical illness. This study aims to test 2 commonly used anti-fracture medications in 450 critically ill women over 50-years of age in Australia. If shown to be effective, this could transform clinical practice, and the recognition and prevention of bone loss in critically ill women.
GO ID:
GO Title:
MRFF Clinical Trials Activity - RCRDUN Initiative – 2019 Rare Cancers, Rare Diseases and Unmet Need Grant Opportunity
Internal Reference ID:
MRF1199726
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
Monash University
Recipient ABN:
12 377 614 012
Grant Recipient Location
Suburb:
Clayton
Town/City:
Clayton
Postcode:
3800
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW, VIC, SA, WA, QLD
Postcode:
Multiple
Country:
AUSTRALIA